{"id":"https://openalex.org/W4381377423","doi":"https://doi.org/10.2337/db23-409-p","title":"409-P: Post Hoc Analyses of Longitudinal Changes of Plasma Proteins Associated with Progression to End-Stage Kidney Disease in Type 2 Diabetes Patients with Chronic Kidney Disease Treated with GLP-1 Receptor Agonist Dulaglutide (AWARD-7)","display_name":"409-P: Post Hoc Analyses of Longitudinal Changes of Plasma Proteins Associated with Progression to End-Stage Kidney Disease in Type 2 Diabetes Patients with Chronic Kidney Disease Treated with GLP-1 Receptor Agonist Dulaglutide (AWARD-7)","publication_year":2023,"publication_date":"2023-06-20","ids":{"openalex":"https://openalex.org/W4381377423","doi":"https://doi.org/10.2337/db23-409-p"},"language":"en","primary_location":{"id":"doi:10.2337/db23-409-p","doi":"https://doi.org/10.2337/db23-409-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db23-409-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016228180","display_name":"Brandon E. McFarlin","orcid":"https://orcid.org/0000-0003-3829-4609","observed_orcids":["https://orcid.org/0000-0003-3829-4609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"BRANDON E. MCFARLIN","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001791944","display_name":"Eiichiro Satake","orcid":"https://orcid.org/0000-0002-9784-4423","observed_orcids":["https://orcid.org/0000-0002-9784-4423"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"EIICHIRO SATAKE","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010470844","display_name":"Zaipul I. Md Dom","orcid":"https://orcid.org/0000-0003-3503-7391","observed_orcids":["https://orcid.org/0000-0003-3503-7391"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ZAIPUL MD DOM","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111199848","display_name":"Joseph J. Ricca","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JOSEPH RICCA","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025843297","display_name":"Afton Kechter","orcid":"https://orcid.org/0000-0002-1228-742X","observed_orcids":["https://orcid.org/0000-0002-1228-742X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"AFTON V. KECHTER","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003206993","display_name":"Jonathan Matthew Wilson","orcid":"https://orcid.org/0000-0002-8648-600X","observed_orcids":["https://orcid.org/0000-0002-8648-600X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JONATHAN M. WILSON","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072130761","display_name":"Kevin L. Duffin","orcid":"https://orcid.org/0000-0002-1656-8982","observed_orcids":["https://orcid.org/0000-0002-1656-8982"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"KEVIN L. DUFFIN","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075863437","display_name":"Andrzej S. Kr\u00f3lewski","orcid":"https://orcid.org/0000-0002-1705-2953","observed_orcids":["https://orcid.org/0000-0002-1705-2953"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANDRZEJ KROLEWSKI","raw_affiliation_strings":["Indianapolis, IN, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indianapolis, IN, Boston, MA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1885,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.49892547,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"72","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10684","display_name":"Acute Kidney Injury Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9850000143051147},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8880000114440918},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.9959999918937683},{"id":"https://openalex.org/keywords/end-stage-kidney-disease-progression","display_name":"end-stage kidney disease progression","score":0.9580000042915344},{"id":"https://openalex.org/keywords/plasma-biomarkers","display_name":"plasma biomarkers","score":0.675000011920929},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8679999709129333},{"id":"https://openalex.org/keywords/insulin-glargine","display_name":"insulin glargine","score":0.9629999995231628},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate","display_name":"estimated glomerular filtration rate","score":0.9210000038146973},{"id":"https://openalex.org/keywords/albumin-creatinine-ratio","display_name":"albumin-creatinine ratio","score":0.9670000076293945},{"id":"https://openalex.org/keywords/treatment-efficacy-biomarker","display_name":"treatment efficacy biomarker","score":0.6159999966621399},{"id":"https://openalex.org/keywords/post-hoc-analysis","display_name":"post hoc analysis","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8388336300849915},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.8240009546279907},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.7394461035728455},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7361158132553101},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.692905843257904},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6170081496238708},{"id":"https://openalex.org/C2779920387","wikidata":"https://www.wikidata.org/wiki/Q417317","display_name":"Insulin glargine","level":4,"score":0.575829803943634},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.568436861038208},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5440279245376587},{"id":"https://openalex.org/C2780306776","wikidata":"https://www.wikidata.org/wiki/Q426660","display_name":"Creatinine","level":2,"score":0.5290504693984985},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.5103341937065125},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.45054566860198975},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.44379886984825134},{"id":"https://openalex.org/C2779922275","wikidata":"https://www.wikidata.org/wiki/Q1129105","display_name":"Diabetic nephropathy","level":3,"score":0.4240246117115021},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.42194628715515137},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3893386125564575},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.2220466136932373},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11124685406684875}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db23-409-p","doi":"https://doi.org/10.2337/db23-409-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db23-409-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4397045286","https://openalex.org/W7125417301","https://openalex.org/W3034422990","https://openalex.org/W2948808633","https://openalex.org/W4319456726","https://openalex.org/W4283317035","https://openalex.org/W3112069718","https://openalex.org/W2889139347","https://openalex.org/W3167335458","https://openalex.org/W3096989852"],"abstract_inverted_index":{"The":[0,75],"AWARD-7":[1,90],"clinical":[2],"trial":[3],"of":[4,77,86,98,139,147,173,224,245,276],"patients":[5,33,69,107,230,236,256],"with":[6,35,60,70,108,156,219,231,238,250,260],"type":[7],"2":[8],"diabetes":[9,71],"(T2D)":[10],"and":[11,26,110,145,163,226,257,284,297,303,309,314],"chronic":[12],"kidney":[13,65,99,221],"disease":[14,66,100],"(CKD)":[15],"reported":[16],"a":[17,37],"slower":[18],"decline":[19],"in":[20,32,68,89,180,194,208,229,235,254],"estimated":[21],"glomerular":[22],"filtration":[23],"rate":[24],"(eGFR)":[25],"decreased":[27],"urinary":[28],"albumin-to-creatinine":[29],"ratio":[30],"(UACR)":[31],"treated":[34,237],"dulaglutide,":[36],"glucagon-like":[38],"peptide-1":[39],"(GLP-1)":[40],"receptor":[41],"agonist,":[42],"compared":[43,212],"to":[44,62,81,91,159,166,184,213],"insulin":[45,121],"glargine":[46,122,181,210],"over":[47],"one":[48],"year.":[49],"Previous":[50],"studies":[51],"identified":[52],"21":[53,140,152],"circulating":[54],"plasma":[55,246],"risk":[56,176,247],"proteins":[57,88,141,153,177,204,216,248,265],"highly":[58],"associated":[59,249],"progression":[61],"end":[63],"stage":[64],"(ESKD)":[67],"(Joslin":[72],"Kidney":[73,269],"Panel).":[74],"aim":[76],"this":[78,241],"study":[79],"was":[80,192,252],"determine":[82],"the":[83,131,137,209,243,261,267],"longitudinal":[84],"changes":[85],"these":[87],"evaluate":[92],"their":[93],"predictive":[94,274],"performance":[95],"as":[96,123,273],"biomarkers":[97,275],"progression.":[101],"Plasma":[102],"samples":[103],"were":[104,154,217],"obtained":[105],"from":[106],"T2D":[109],"CKD":[111],"stages":[112],"3-4":[113],"who":[114],"received":[115],"dulaglutide":[116,195],"1.5":[117],"mg":[118],"(n=124)":[119],"or":[120],"basal":[124],"therapy":[125],"(n=125)":[126],"for":[127],"52":[128,201],"weeks.":[129,199],"Using":[130],"Olink":[132],"custom":[133],"platform":[134],"we":[135],"measured":[136],"concentration":[138],"at":[142,197],"baseline,":[143],"26-weeks,":[144],"52-weeks":[146],"treatment.":[148],"At":[149],"baseline":[150],"all":[151,161,168,186],"correlated":[155,218],"eGFR":[157],"(r=-0.2":[158],"-0.8;":[160],"p<0.0003)":[162],"UACR":[164,228],"(r=0.2":[165],"0.6;":[167],"p<0.0001).":[169],"After":[170],"26":[171,198],"weeks":[172],"treatment,":[174],"13":[175],"significantly":[178,206],"increased":[179],"group":[182,196,211],"(3":[183],"13%;":[185],"p<0.05)":[187],"whereas":[188],"no":[189],"significant":[190],"change":[191],"observed":[193],"By":[200],"weeks,":[202],"5":[203],"remained":[205],"elevated":[207],"dulaglutide.":[214,239],"Several":[215],"declining":[220],"function":[222],"(change":[223],"eGFR)":[225],"increasing":[227],"glargine,":[232],"but":[233],"not":[234],"In":[240],"study,":[242],"increase":[244],"ESKD":[251],"slowed":[253],"dulaglutide-treated":[255],"is":[258],"consistent":[259],"hypothesis":[262],"that":[263],"several":[264],"within":[266],"Joslin":[268],"Panel":[270],"can":[271],"serve":[272],"treatment":[277],"efficacy.":[278],"Disclosure":[279],"B.E.Mcfarlin:":[280],"Employee;":[281,294,300,306],"Eli":[282,295,301,307,312],"Lilly":[283,296,302,308,313],"Company.":[285,298,304],"E.Satake:":[286],"None.":[287,290,292,319],"Z.Md":[288],"dom:":[289],"J.Ricca:":[291],"A.V.Kechter:":[293],"J.M.Wilson:":[299],"K.L.Duffin:":[305],"Company,":[310,315],"Stock/Shareholder;":[311],"Pfizer":[316],"Inc.":[317],"A.Krolewski:":[318]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-06-21T00:00:00"}